World's Best Scientists 2026 revealed!
Georgina V. Long

Georgina V. Long

Award Badge
Best Female Scientists
2025
Award Badge
Medicine
Australia
2023

D-Index & Metrics

Best Female Scientists

D-Index
136
Citations
117295
World Ranking
267
National Ranking
10

Medicine

D-Index
139
Citations
119505
World Ranking
1716
National Ranking
47

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award
  • 2023 - Research.com Medicine in Australia Leader Award

Overview

Georgina V. Long is affiliated with the University of Sydney in Australia. Their research spans several interconnected fields within medicine and biomedicine, focusing heavily on oncology and molecular biology. The primary domains of Long's work include cancer immunotherapy, melanoma, and molecular mechanisms underlying cancer progression.

The main fields of study for Long's publications are Medicine and Biochemistry, Genetics and Molecular Biology. Their subfields include:

  • Oncology
  • Molecular Biology
  • Immunology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Long's research topics are centered on:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Melanoma and MAPK Pathways
  • Cutaneous Melanoma Detection and Management
  • Immunotherapy and Immune Responses
  • Cancer Genomics and Diagnostics
  • Brain Metastases and Treatment

Their publication record includes notable recent papers such as:

  • "Immune checkpoint inhibitors in melanoma," 2021, The Lancet
  • "Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma," 2022, Zurich Open Repository and Archive (University of Zurich)
  • "Cutaneous melanoma," 2023, The Lancet
  • "Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study," 2024, The Lancet
  • "Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo," 2020, JAMA Oncology

Frequent coauthors in Long's work include:

  • Alexander M. Menzies
  • Richard A. Scolyer
  • Matteo S. Carlino
  • Paolo A. Ascierto
  • Dirk Schadendorf

Long has published extensively in several prominent scientific venues. The most frequent publication venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • Cancer Research
  • Journal for ImmunoTherapy of Cancer

Best Publications

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Nivolumab in previously untreated melanoma without BRAF mutation.

    Caroline Robert;Georgina V. Long;Benjamin Brady;Caroline Dutriaux

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Genomic Classification of Cutaneous Melanoma

    Rehan Akbani;Kadir C. Akdemir;B. Arman Aksoy;Monique Albert

  • Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

    Katherine A. Hoadley;Christina Yau;Christina Yau;Toshinori Hinoue;Denise M. Wolf

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

    Daniel Y. Wang;Joe Elie Salem;Joe Elie Salem;Justine V. Cohen;Sunandana Chandra

  • Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

    Jeffrey E. Gershenwald;Richard A. Scolyer;Kenneth R. Hess;Vernon K. Sondak

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

    Antoni Ribas;Reinhard Dummer;Igor Puzanov;Ari VanderWalde

  • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

    G. V. Long;A. Hauschild;M. Santinami;V. Atkinson

  • Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

    Jeffrey S. Weber;F. Stephen Hodi;Jedd D. Wolchok;Suzanne L. Topalian

  • Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Jacob Schachter;Antoni Ribas;Georgina V. Long;Ana Arance

Frequent Co-Authors

Richard A. Scolyer
Richard A. Scolyer Royal Prince Alfred Hospital
Alexander M. Menzies
Alexander M. Menzies University of Sydney
Matteo S. Carlino
Matteo S. Carlino University of Sydney
Richard F. Kefford
Richard F. Kefford Macquarie University
John F. Thompson
John F. Thompson University of Sydney
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
James S. Wilmott
James S. Wilmott University of Sydney
Caroline Robert
Caroline Robert University of Paris-Saclay
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Helen Rizos
Helen Rizos Macquarie University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA doesn’t always mean following the traditional path to becoming a doctor. There are a variety of related degrees and industries offering flexible, online options for students interested in healthcare and medicine.

For aspiring nurses looking to advance their clinical expertise, exploring the most affordable online dnp programs is a great way to earn a Doctor of Nursing Practice. Another popular path is pharmacy, with several online pharmacy schools that help students become pharmacists while balancing work or family commitments.

Those interested in the business and technology side of medicine might consider a him associate degree online. This degree opens doors to roles in medical data and healthcare administration. Beginners can also start with essential medical billing and coding classes online, building critical skills for hospitals, clinics, and insurance companies.

Online healthcare degrees allow students to gain specialized knowledge, improve job prospects, and make meaningful contributions to the medical field—all with increased flexibility and affordability.

Best Scientists Citing Georgina V. Long

Trending Scientists

Recently Published Articles